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Abstract
Purpose Even with statins and other lipid-lowering therapy
(LLT), many patients with heterozygous familial hypercholes-
terolemia (heFH) continue to have elevated low-density lipo-
protein cholesterol (LDL-C) levels. ODYSSEY HIGH FH
(NCT01617655) assessed the efficacy and safety of
alirocumab, a proprotein convertase subtilisin/kexin type 9
monoclonal antibody, versus placebo in patients with heFH
and LDL-C ≥ 160 mg/dl despite maximally tolerated statin ±
other LLT.
Methods Patients were randomized to subcutaneous
alirocumab 150 mg or placebo every 2 weeks (Q2W) for
78 weeks. The primary endpoint was percent change in
LDL-C from baseline to week 24.
Results Mean baseline LDL-C levels were 196.3 mg/dl in the
alirocumab (n = 71) and 201.0 mg/dl in the placebo groups
(n = 35). Significant mean (standard error [SE]) reductions in
LDL-C from baseline to week 24 were observed with
alirocumab (−45.7 [3.5] %) versus placebo (−6.6 [4.9] %), a
difference of −39.1 (6.0) % (P < 0.0001). Absolute mean (SE)
LDL-C levels were reduced from baseline by 90.8 (6.7) mg/dl
with alirocumab at week 24, with reductions maintained to
week 78. Treatment-emergent adverse events were generally
comparable between groups. Injection-site reactions were
more frequent in the alirocumab group (8.3 %) versus placebo
(5.7 %); most were mild in severity and did not result in study
medication discontinuation.
Conclusions In patients with heFH and very high LDL-C
baseline levels despite maximally tolerated statin ± other
LLT, alirocumab 150 mg Q2W demonstrated significant re-
ductions in LDL-C levels with 41 % of patients achieving
predefined LDL-C goals. Alirocumab was generally well
tolerated.
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Introduction
Heterozygous familial hypercholesterolemia (heFH) is associ-
ated with high levels of low-density lipoprotein cholesterol
(LDL-C), which predisposes to premature atherosclerosis
and cardiovascular disease [1, 2]. LDL-C levels can be in
the range of ~200–400 mg/dl (5–10 mmol/L) if untreated
and are >160 mg/dl (4.14 mmol/L) in a number of affected
adults, despite treatment with available lipid-lowering thera-
pies (LLTs) [3, 4]. Due to lifelong exposure to elevated LDL-
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C plasma levels, patients with heFH are characterized by a
markedly increased risk of coronary heart disease compared
with the general population [1].
Current LDL-C-lowering treatments include statins and
ezetimibe, which have both been shown to contribute to a
reduction of coronary mortality [5, 6]. Other LLTs, such as
bile acid sequestrants and fibrates, may also be added to statin
therapy to further reduce LDL-C levels [7]. However, despite
treatment with the current standard of care, many patients with
heFH struggle to achieve sufficient LDL-C reductions, with
previous research reporting that only ~20 % of patients with
heFH achieved a pre-defined LDL-C target level of <100 mg/
dl with existing cholesterol-lowering treatment options [7, 8].
Proprotein convertase subtilisin/kexin type 9 (PCSK9) tar-
gets the degradation of hepatic LDL receptors, thereby reduc-
ing the ability of the liver to remove LDL-C from the circula-
tion [9]. Inhibitors of PCSK9 are now available in the United
States and Europe to reduce LDL-C in patients with heFH,
atherosclerotic cardiovascular disease, and/or cardiovascular
risk factors [10–13]. In phase 1 studies, usually conducted in a
limited number of highly selected investigator sites, PCSK9
inhibitors have been shown to reduce LDL-C levels in patients
with heFH [14, 15]. Results from phase 2 and 3 studies to date
with the fully human monoclonal PCSK9 antibody
alirocumab have demonstrated considerable potential for the
reduction of LDL-C levels in different patient populations [11,
16–25], with significant reductions in mean LDL-C levels of
68 % observed in a phase 2 study that included patients with
heFH (placebo: 11 %) [11]. In the phase 3 ODYSSEY pro-
gram, a large proportion of patients with heFH were included
(>1200 patients); in three studies published to date,
alirocumab demonstrated significant LDL-lowering in pa-
tients with heFH [19, 25].
The phase 3 ODYSSEY HIGH FH study was a placebo-
controlled study evaluating the lipid-lowering efficacy and
safety of alirocumab 150 mg every 2 weeks (Q2W) as add-
on therapy in patients with heFH and baseline levels of LDL-
C ≥ 160 mg/dl despite maximally tolerated statin therapy
(with or without other LLTs). The results of ODYSSEY
HIGH FH are presented here.
Methods
The ODYSSEY HIGH FH study was a multicenter, ran-
domized, double-blind, placebo-controlled, phase 3 trial
(ClinicalTrials.gov identifier: NCT01617655). It was
conducted at 33 sites across Canada, the United States,
the Netherlands, Russia, and South Africa from
June 2012 to January 2015. The study was performed
in accordance with the ethical principles that have their
origin in the Declaration of Helsinki and all applicable
amendments la id down by the World Medical
Assembl i e s and the In t e rna t iona l Confe rence
Harmonization guidelines for Good Clinical Practice.
The protocol was approved by the local institutional
review board and independent ethics committee at each
site, and all patients provided written informed consent
prior to participation.
Patients
Full details of the inclusion and exclusion criteria for the
ODYSSEY HIGH FH trial have been published previously
[10]. Briefly, patients with heFH and LDL-C ≥ 160 mg/dl on a
maximally tolerated stable daily dose of statin, with or without
other LLT, for at least 4 weeks (6 weeks for fenofibrate) prior
to the screening visit were included.
The diagnosis of heFH was made by either genotyp-
ing (17.8 %) or clinical criteria (82.2 %) (Table 1). For
those patients not genotyped, the clinical diagnosis was
based on either Simon Broome criteria for definite FH
[26], or the World Health Organization/Dutch Lipid
Network criteria (score > 8 points) [27].
Maximally tolerated statin therapy included daily
doses of simvastatin (80 mg, if on this dose for
>1 year), atorvastatin (40–80 mg), or rosuvastatin (20–
40 mg). Patients not on any of these statin doses were
treated with the dose of daily atorvastatin, rosuvastatin,
or simvastatin which was considered appropriate for the
patient, according to the investigator’s judgment.
Additional exclusion criteria were fibrates (other than
fenofibrate), fasting serum triglycerides >400 mg/dl
(4.52 mmol/L) and known history of homozygous FH.
Study Design
Following a screening period of up to 3 weeks, all
eligible patients were randomized 2:1 to alirocumab
150 mg Q2W administered subcutaneously via 1 ml pre-
fi l led pen, or matching placebo, for 78 weeks
(Supplementary Fig. 1). Randomization was stratified
according to history of myocardial infarction or ische-
mic stroke, as well as intensity of statin treatment (ator-
vastatin 40–80 mg daily, rosuvastatin 20–40 mg daily
vs. s imvastat in , atorvastat in <40 mg dai ly, or
rosuvastatin <20 mg daily). At the end of the 78-week
double-blind treatment period, patients could enter an
open-label extension study, during which they all re-
ceived alirocumab 150 mg Q2W. Those patients opting
out of the open-label treatment period underwent an 8-
week follow-up. Patients were asked to adhere to a sta-
ble diet in line with the National Cholesterol Education
Program Adult Treatment Panel III Therapeutic Lifestyle
Changes diet or equivalent, and received statin therapy
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at the maximally tolerated daily dose with or without
other LLT throughout the study.
Endpoints and Assessments
The primary efficacy endpoint was the percent change in cal-
culated LDL-C from baseline to week 24 analyzed with the
use of an intent-to-treat (ITT) approach. Secondary efficacy
endpoints included LDL-C percent change from baseline to
week 24 (on-treatment analysis) and from baseline to weeks
12, 52, and 78 (ITT); percent change in non-high-density li-
poprotein cholesterol (non-HDL-C), total cholesterol, HDL-
C, apolipoprotein B, lipoprotein (a) [Lp(a)], and triglycerides;
the proportion of patients achieving LDL-C < 70 mg/dl
(1.81 mmol/L) or < 100 mg/dl (2.59 mmol/L); and the pro-
portion of patients with LDL-C < 70 mg/dl and/or a ≥ 50 %
reduction in calculated LDL-C.
On-site assessments were performed at baseline (week 0)
and then weeks 12, 24, 36, 52, 64, 78, and the end-of-study
visit, week 86, for patients not entering the open-label exten-
sion study. Fasting blood samples for lipid analysis were col-
lected in the morning. Lipid analyzes were performed at a
central laboratory and LDL-C was calculated using the
Friedewald formula [28].
Table 1 Baseline characteristics (all randomized patients)






Age, years, mean (SD) 49.8 (14.2) 52.1 (11.2)
Male, % (n) 48.6 (35) 62.9 (22)
Race, White, % (n) 88.9 (64) 85.7 (30)
BMI, kg/m2, mean (SD) 28.8 (5.2) 28.9 (4.2)
Confirmation of heFH diagnosis by genotyping, % (n) 19.4 (14) 14.3 (5)
Confirmation of heFH diagnosis by WHO/Simon Broome criteria, % (n) 80.6 (58) 85.7 (30)
CHD history, % (n) 43.1 (31) 62.9 (22)
CHD risk equivalent,a % (n) 18.1 (13) 14.3 (5)
Hypertension, % (n) 55.6 (40) 60.0 (21)
Type II diabetes, % (n) 12.5 (9) 17.1 (6)
Current smoker, % (n) 16.7 (12) 25.7 (9)
Lipid medication
Statin use, % (n) 100 (72) 100 (35)
High-intensity statin use,b % (n) 73.6 (53) 71.4 (25)
Simvastatin 80 mg, % (n) 5.6 (4) 8.6 (3)
Other LLT use, % (n) 22.2 (16) 37.1 (13)
Ezetimibe use, % (n) 19.4 (14) 34.3 (12)
Baseline lipid parameters, mg/dl
LDL-C (calculated), mean ± SD 196.3 ± 57.9c 201.0 ± 43.4
Non-HDL-C, mean ± SD 223.9 ± 58.8 231.5 ± 47.6
Total cholesterol, mean ± SD 273.5 ± 57.5 276.4 ± 46.8
ApoB, mean ± SD 138.2 ± 32.0c 146.6 ± 28.3d
Lp(a), median (Q1:Q3) 22.0 (8.0:50.0)c 30.0 (11.0:42.0)d
HDL-C, mean ± SD 49.6 ± 14.0 44.9 ± 11.3
Fasting TGs, median (Q1:Q3) 131.5 (87.5:160.5) 122.0 (95.0:193.0)
Apo apolipoprotein, BMI body mass index, CHD coronary heart disease, HDL-C high-density lipoprotein cholesterol, heFH heterozygous familial
hypercholesterolemia, LDL-C low-density lipoprotein cholesterol, LLT lipid-lowering therapy, Lp(a), lipoprotein(a), Q2W every 2 weeks, SD standard
deviation, TGs triglycerides, WHOWorld Health Organization
a CHD risk equivalents were defined as ischemic stroke, peripheral arterial disease, moderate chronic kidney disease, and diabetes mellitus (only if two or
more risk factors present)
b High-intensity statin therapy was defined as atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily
c n = 71
d n = 34
Cardiovasc Drugs Ther (2016) 30:473–483 475
Safety
Safety was assessed by monitoring adverse events (AEs), se-
rious AEs, laboratory parameters, vital signs, and anti-
alirocumab antibody development. Treatment emergent AEs
(TEAEs) were defined as AEs that occurred, worsened, or
became serious during the period from first to last injection
(+70 days), or to the first injection in the open-label extension
study, whichever came first.
AEs of special interest included allergic events, local
injection-site reactions, hemolytic anemia, increases in alanine
aminotransferase, neurologic disorders, neurocognitive
events, ophthalmological disorders, and adjudicated cardio-
vascular events (categorized as coronary heart disease death,
non-fatal myocardial infarction, fatal and non-fatal ischemic
stroke, unstable angina requiring hospitalization and conges-
tive heart failure requiring hospitalization). Pre-dose samples
were obtained at baseline and several time points up to the end
of study for assessment of anti-alirocumab antibodies, per-
formed by the Regeneron Clinical Bioanalysis Group
(Regeneron Pharmaceuticals, Inc. Tarrytown, NY, USA).
Statistical Analysis
A sample size of 45 patients was calculated to have 95 %
power to detect a difference of at least 30 % in mean percent
change from baseline in LDL-C at week 24 with 5 % two-
sided significance level, assuming a common standard devia-
tion of 25 % (based on previous experience with alirocumab
[16]). Nevertheless, to meet regulatory requirements across
the program, this sample size was increased to 105 patients
to assess the safety of alirocumab.
The primary efficacy endpoint was analyzed in the ITT
population, defined as all randomized patients with at least
one calculated LDL-C value at baseline and at least one avail-
able calculated LDL-C value within one of the analysis win-
dows up to week 24. A pre-specified on-treatment analysis
was also performed, which excluded patients from the ITT
population lacking an LDL-C value obtained while receiving
study treatment (up to 21 days after last injection). A mixed
effect model with repeated measures approach to account for
missing data [29, 30] was used to provide least-squares (LS)
means estimates within each treatment arm and for the com-
parison between treatment arms for the primary and continu-
ous secondary efficacy endpoints, (except Lp(a) and triglyc-
erides), with a hierarchical procedure used to control type I
error and handle multiple secondary endpoint analyzes. Lp(a)
and triglycerides were analyzed using a multiple imputation
approach to handle missing data, followed by robust regres-
sion [31]. The proportion of patients achieving pre-defined
LDL-C goals was analyzed using a multiple imputation ap-
proach to handle missing data followed by stratified condi-
tional logistic regression model with treatment group as the
main effect, baseline LDL-C value as covariate, and stratified
Fig. 1 Patient flow through the study. aIncludes 14 patients (alirocumab
n = 12; placebo n = 2) who completed the 18 months double-blind treat-
ment period (at least 76 weeks of exposure and visit week 78 performed)
but did not meet the definition of Bcompleter per CRF ,^ eight patients
with site closure/site location unavailable (alirocumab n = 5; placebo
n = 3), three alirocumab-treated patients with other reasons (not willing
to continue the study [no specific reason provided] n = 1; new job too far
from research unit n = 1; withdrawal due to cholesterol results done
independently n = 1). All patients on background of maximally tolerated
statin ± other lipid-lowering therapy AE, adverse event; CRF, case report
form; ITT, intent-to-treat; Q2W, every 2 weeks
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by the randomization factors. A sensitivity analysis of the
primary endpoint using a pattern mixture model was also con-
ducted to assess the robustness of used statistical methods.
Missing calculated LDL-C values during the on-treatment pe-
riod were multiply imputed using a model assuming ‘missing
at random’, and missing calculated LDL-C values during the
post-treatment period were multiply imputed using random
draws from a normal distribution where the mean was equal
to the subject’s own baseline value.
An additional post-hoc sensitivity analysis was con-
ducted excluding patients from three study sites with
serious Good Clinical Practice non-compliance.
All randomized and treated patients were included in the
safety analyzes. Safety data were analyzed by descriptive sta-
tistics. All statistical analyzes were conducted using SAS®
(SAS® Institute Inc., Cary, NC).
All lipid measurements and clinical laboratory tests
were performed using standard procedures by a central
laboratory (Medpace), which was standardized by, and




In total, 107 eligible patients were randomized to treatment
with alirocumab (n = 72) or placebo (n = 35) (Fig. 1). Baseline
characteristics and lipid parameters of randomized patients
(Table 1) were generally similar between the groups, although
some imbalances were observed in terms of gender, propor-
tion of patients with coronary heart disease or risk equivalents,
and patients receiving ezetimibe as additional background
LLT. In both groups, all patients received background statin
therapy, with 72.9 % of all patients receiving high-intensity
statin. In addition, 27.1% of patients were also receiving other
LLTs (overall, 24.3 % of patients were receiving ezetimibe
[19.4 % alirocumab; 34.3 % placebo]). A total of 73.6 % of
patients in the alirocumab group and 77.1 % in the placebo
group completed the double-blind treatment period (at least
76 weeks of exposure and visit week 78 performed). Over the
78-week treatment period, the compliance to study medication
was similar between treatment groups (97.8 % alirocumab;
96.9 % placebo). Three of 33 study sites, with a total of 20
randomized patients (alirocumab: n = 15; placebo: n = 5),
were closed due to serious breach of compliance with Good
Clinical Practice.
Efficacy
At week 24, the LS mean (standard error [SE]) percent change
in LDL-C from baseline was greater in the alirocumab add-on
group (−45.7 [3.5] %) compared with the placebo group (−6.6
[4.9] %) in the ITT population, with a statistically significant
LS mean (SE) difference between the groups of −39.1 (6.0) %
(P < 0.0001; Table 2 and Fig. 2). The results for the on-
treatment analysis were similar at week 24 (alirocumab −45.5
[3.5] %; placebo −6.6 [5.0] %; P < 0.0001) (Supplementary
Table 1). A sensitivity analysis was conducted excluding pa-
tients from the three non-compliant sites and demonstrated LS
mean (SE) percent decrease from baseline to week 24 with
alirocumab (−50.9 [3.4] %) vs. placebo (−1.0 [4.7] %) in
LDL-C (LS mean difference vs. placebo −49.8 [5.8] %;
P < 0.0001) (Fig. 2 and Supplementary Table 2).
The reduction in LDL-C with alirocumab allowed 41.0 %
of patients to achieve their pre-defined LDL-C target levels of
< 70 or 100 mg/dl (depending on cardiovascular risk) at week
24, compared with only 5.7 % of patients in the placebo arm;
LDL-C levels of < 70 mg/dl were achieved by 32.4 % and
2.9 % of patients, respectively (ITT analysis). In the on-
treatment analysis, 50.7 % of patients in the alirocumab arm
versus 11.4 % in the placebo arm reached a calculated LDL-C
level of < 100 mg/dl, regardless of risk at week 78. The cal-
culated LDL-C levels over time in the alirocumab and placebo
arms from baseline to week 78 are shown in Fig. 3:
alirocumab maintained consistent LDL-C reductions over
the course of the study, with the reductions observed by week
4 remaining largely constant through 78 weeks of treatment.
The LS mean (SE) absolute reduction in LDL-C levels from
baseline to week 24 with alirocumab was 90.8 (6.7) mg/dl
(75.3 [11.6] mg/dl vs. placebo).
A sensitivity analysis of the primary endpoint using the
pattern mixture model to handle missing data showed consis-
tent results with the primary analysis (Supplementary
Table 3).
At week 24, significant reductions from baseline versus
placebo were also observed in non-HDL-C (alirocumab:
−41.9 [3.1] %; placebo: −6.2 [4.3] %; P < 0.0001), total cho-
lesterol (alirocumab: −33.2 [2.6] %; placebo: −4.8 [3.6] %;
P < 0.0001), apolipoprotein B (alirocumab: −39.0 [2.7] %;
placebo: −8.7 [3.8] %; P < 0.0001), and Lp(a) (alirocumab:
−23.5 [3.7] %; placebo: −8.7 [5.0] %; P = 0.0164) in patients
receiving alirocumab (Table 2). No significant changes were
observed for either HDL-C (alirocumab: 7.5 [1.9] %; placebo:
3.9 [2.7] %) or triglyceride levels (alirocumab: −10.5 [3.3] %;
placebo: −1.9 [4.8] %) (Table 2). At week 78, reductions with
alirocumab compared with placebo were observed for Lp(a),
non-HDL-C, apolipoprotein B, and total cholesterol
(Supplementary Table 4).
Safety
Overall, 70.8 % of patients in the alirocumab group experienced
a TEAE compared with 80.0 % in the placebo group (Table 3).
There were no reported deaths. A total of five patients
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prematurely discontinued the treatment following at least one
TEAE (three patients [4.2 %] in the alirocumab add-on group
and two patients [5.7 %] in the placebo group) with no specific
clinical pattern. The percentages of patients experiencing
treatment-emergent serious AEs were similar in the alirocumab
(13.9 %) and placebo (11.4 %) groups (Table 3). The TEAEs
occurring in ≥2% of patients in either the alirocumab or placebo
group are shown in Supplementary Table 5.
Considering the TEAEs of special interest, a similar propor-
tion of patients in both groups experienced potential general
allergic (alirocumab 6.9 % [n = 5]; placebo 5.7 % [n = 2]) and
neurological events (alirocumab 2.8 % [n = 2]; placebo 2.9 %
[n = 1]) (Table 3). One patient in each group reported a
neurocognitive event: disturbance in attention in one
alirocumab-treated patient (1.4 %) and amnesia in one placebo
patient (2.9 %). Injection-site reactions were reported by 8.3 %
(n = 6) of patients in the alirocumab group (vs. 5.7 % [n = 2]
placebo); most were mild in severity and did not result in study
medication discontinuation. One patient in the alirocumab-
treated group experienced an ophthalmological TEAE
(chorioretinopathy). The investigator and sponsor considered
the event not to be related to the investigational medicinal prod-
uct, statin, or other LLT. No cases of confirmed hemolytic ane-
mia were reported. Hepatic disorders were experienced by a
similar proportion of patients in the alirocumab and placebo
groups (5.6–8.6 % [n = 3–4]). TEAEs related to the worsening
or development of diabetes (diabetes mellitus or diabetic com-
plication) were reported in one patient in each treatment group
(alirocumab: 1.4 %; placebo: 2.9 %). Adjudicated treatment-
emergent cardiovascular events were reported in six (8.3 %)
alirocumab-treated patients (vs. no placebo patients) as follows:
non-fatal myocardial infarction (n = 4), coronary heart failure
requiring hospitalization (n = 1) and ischemia-driven coronary
revascularization procedure (n = 5).
A total of four patients (5.6 %) in the alirocumab-treated
group had LDL-C values of < 25 mg/dl (0.65 mmol/L) on at
least two consecutive occasions; one of those patients experi-
enced two consecutive LDL-C values < 15 mg/dl (0.39 mmol/
L). One patient experienced chorioretinopathy at week 44,
10months after the first study drug administration, during which
the LDL-C level remained < 25mg/dl fromweeks 4–24 andwas
at 53 mg/dl at week 52. No other specific safety concerns were
identified in patients with LDL-C values of < 15 or < 25 mg/dl.
Anti-Alirocumab Antibodies
Administration of alirocumab 150 mg Q2W for 78 weeks was
associatedwith low levels of immunogenicity. No patients had
Table 2 Effect of alirocumab versus placebo on LDL-C, secondary lipid parameters, and achievement of LDL-C target levels at week 24 (ITT
analysis)











95 % CI P value
Week 24
Absolute LDL-C level (SE), mg/dl 107.0 (6.7) 182.3 (9.5)
Absolute change (SE) from baseline, mg/dl −90.8 (6.7) −15.5 (9.5) −75.3 (11.6) −98.4 to −52.2 <0.0001
LS mean (SE) change in calculated LDL-C from baseline to week 24 −45.7 (3.5) −6.6 (4.9) −39.1 (6.0) −51.1 to −27.1 <0.0001*
Proportion of very high CV risk patients reaching calculated LDL-C < 70 mg/dl or
high CV risk patients reaching calculated LDL-C < 100 mg/dl, %
41.0a 5.7a 0.0016*
% change from baseline to week 24 in other lipid parameters, LS mean (SE)
Non-HDL-C −41.9 (3.1) −6.2 (4.3) −35.8 (5.3) −46.3 to −25.3 <0.0001*
ApoB −39.0 (2.7)b −8.7 (3.8)c −30.3 (4.7) −39.7 to −20.9 <0.0001*
Total cholesterol −33.2 (2.6) −4.8 (3.6) −28.4 (4.4) −37.3 to −19.6 <0.0001*
Lp(a)d −23.5 (3.7) −8.7 (5.0) −14.8 (6.2) −26.9 to −2.7 0.0164*
HDL-C 7.5 (1.9) 3.9 (2.7) 3.7 (3.3) −2.9 to 10.2 0.2745
TGsd −10.5 (3.3) −1.9 (4.8) −8.7 (5.9) −20.2 to 2.8 0.1386
The P value is followed by a ‘*’ if statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type-I
error rate at the 0.05 level
Apo, apolipoprotein; CI, confidence interval; CV, cardiovascular;CVD, cardiovascular disease;HDL-C, high-density lipoprotein cholesterol; ITT, intent-
to-treat; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); LS, least squares; Q2W, every 2 weeks; SE, standard error; TGs, triglycerides
a Combined estimate for proportion of patients reaching the level
b n = 69
c n = 34
d Combined estimate for adjusted proportion
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pre-existing immunoreactivity. Positive responses in the anti-
drug antibody (ADA) assay were observed in two patients,
one in each group (alirocumab: 1/50 [2.0 %], placebo 1/29
[3.4 %]). In the alirocumab patient, the ADA assay response
was transient, detected at a single time point (week 52), and
drug efficacy was not affected since the LDL-C reduction
from baseline was maintained at 40 % over the study duration
including at week 52. Furthermore, the ADA assay response
in this patient was very low (minimum titer in the assay). In
the patient from the placebo group, a positive ADA assay
response was observed at weeks 52 and 78. Since this patient
was not administered alirocumab, this signal was most likely
Fig. 2 LDL-C percent change from baseline to week 24: comparison
with patients with heFH from ODYSSEY LONG TERM and patients
from ODYSSEY FH I and II with LDL-C baseline ≥ 160 mg/dl aAll
patients were on background of maximally tolerated statin ± other LLT
bExcluding non-Good Clinical Practice compliant sites cA total of 70.9 %
(FH I) and 80.0% (FH II) of the alirocumab-treated patients with baseline
LDL-C ≥ 160 mg/dl received dose adjustment from 75 mg Q2W to
150 mg Q2W at week 12. ITT, intent-to-treat; LLT, lipid-lowering thera-
py; LS, least squares; SE, standard error
Fig. 3 LDL-C levels over time
(ITT analysis). Values above data
points indicate calculated LDL-C
(LS mean, mg/dl). All patients on
background of maximally tolerat-
ed statin ± other lipid-lowering
therapy. LDL-C, low-density li-
poprotein cholesterol; LS, least
squares; Q2W, every 2 weeks;
SE, standard error
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due to high serum background levels in the ADA assay and
not a drug-induced ADA response. None of the samples pos-
itive in the ADA assay were neutralizing.
Discussion
In this study of patients with heFH and very high baseline
levels of LDL-C, despite maximally tolerated statins ± other
LLT, alirocumab 150 mg Q2W demonstrated significant re-
ductions in LDL-C levels compared with placebo, achieving a
mean absolute LDL-C reduction of 90.8 mg/dl at week 24.
The LDL-C reduction from baseline to week 24 in the
current study was −45.7 % with alirocumab 150 mg Q2W
(vs. placebo: −6.6 %); this compared with a reduction of
−52.2 % with alirocumab 150 mg Q2W (placebo: −8.1 %)
in the subset of patients with heFH from ODYSSEY LONG
TERM with high baseline LDL-C levels of ≥ 160 mg/dl
(the changes from baseline for the overall study population
in LONG TERM were −61.0 % for alirocumab and 0.8 %
for placebo) (Fig. 2). In a separate pool of patients with
baseline LDL-C levels of ≥ 160 mg/dl from studies
ODYSSEY FH I & II, alirocumab 75 mg Q2W (with possible
dose adjustment to 150 mg Q2W) demonstrated a slightly
higher LDL-C reduction (alirocumab: −56.6 %; placebo:
Table 3 AEs and safety laboratory values (safety population)





TEAEs,a % (n) 70.8 (51) 80.0 (28)
Treatment-emergent SAEs, % (n) 13.9 (10) 11.4 (4)
TEAEs leading to death, % (n) 0 0
TEAEs leading to treatment discontinuation, % (n) 4.2 (3) 5.7 (2)
AEs of interest
Any local injection-site reaction,b % (n) 8.3 (6) 5.7 (2)
Mild intensity 83.3 (5) 100 (2)
Moderate intensity 16.7 (1) 0
Severe intensity 0 0
Potential general allergic events, % (n) 6.9 (5) 5.7 (2)
Neurological events, % (n) 2.8 (2) 2.9 (1)
Neurocognitive disorders, % (n) 1.4 (1) 2.9 (1)
Ophthalmologic disorders, % (n) 1.4 (1) 0
Positively adjudicated CVevents, % (n) 8.3 (6) 0
CHD death 0 0
Non-fatal MI 5.6 (4) 0
Ischemic stroke 0 0
Unstable angina requiring hospitalization 0 0
CHF requiring hospitalization 1.4 (1) 0
Ischemia-driven coronary revascularization procedure 6.9 (5) 0
Type II diabetes 1.4 (1) 2.9 (1)








Creatine kinase >3 times ULN 2.8 (2)c 2.9 (1)
AE, adverse event; CHD, coronary heart disease; CHF, coronary heart failure;CV, cardiovascular;MI, myocardial infarction;Q2W, every 2 weeks; SAE,
serious adverse event; TEAE, treatment-emergent adverse event; ULN, upper limit of normal
a TEAEs are AEs that developed or worsened or became serious during the TEAE period (time from first dose of double-blind treatment to last dose
+70 days or first dose of open-label treatment, whichever came first). More than one TEAE may be reported per patient
b In case of several occurrences, the maximal intensity was used
c n = 71
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1.7 %) (Fig. 2). Significant reductions in LDL-C levels have
also been seen with a bi-weekly or four-weekly dosing regi-
men of another PCSK9 inhibitor, evolocumab, in patients with
HeFH and either with or without statin intolerance [12, 13,
33–35].
The HIGH FH study was designed to assess the effica-
cy and safety in a specific group of patients with a par-
ticularly high level of LDL-C at screening and a sufficient
number of patients were included in the current study for
the purposes of assessing the primary endpoint, LDL-C
percentage change at week 24 for alirocumab versus pla-
cebo (−39.1 %, P < 0.0001). This was lower than reduc-
tions seen in other studies in the overall ODYSSEY pro-
gram, including those with FH patients, and it is important
to consider the potential reasons for this difference. One
possibility is that patients enrolled in HIGH FH differed
from HeFH patients in other ODYSSEY trials [19]. For
example, a smaller proportion of HIGH FH patients were
on high-intensity statin and ezetimibe compared with
HeFH patients in other ODYSSEY studies [19]. We are
unsure as to why this occurred, although intolerance to
ezetimibe could have been one reason for these patients
having LDL-C levels of 160 mg/dL or greater. Whatever
the reason, generalization of these findings with respect to
efficacy should be viewed with this difference in back-
ground therapy taken into consideration. Additionally, the
relatively low number of patients randomized to placebo
(n = 35) resulted in a higher variability in results which might
not be seen in a larger study. In fact, the placebo-corrected
observations of a number of participants were influenced by
significant reductions in the placebo arm. Finally, three of the
study sites (with 20 randomized patients) were closed due to
serious breaches of compliance with Good Clinical Practice;
when these sites were omitted in a sensitivity analysis, greater
reductions in LDL-C levels from baseline were seen with
alirocumab (−49.8 % vs. placebo; alirocumab: −50.9 %, pla-
cebo: −1.0 %; a difference of over 10 percentage points com-
pared with the primary analysis).
The small size of HIGH FH also does not allow for conclu-
sive safety observations to be made, in particularly for the rare
adverse events. As a consequence, safety results should be
interpreted with caution and must be considered in the context
of larger studies and the ODYSSEYprogram as a whole.
With LDL-C baseline levels of 196.3–201.0 mg/dl in pa-
tients on maximum-tolerated statin ± other LLT, this study
population reflected one at significantly increased risk of car-
diovascular events and in need of further treatment to reduce
LDL-C. Importantly, these patients with heFH receiving
alirocumab achieved a mean absolute LDL-C reduction of
90.8 mg/dl at week 24 in patients with heFH. These large
reductions in LDL-C levels were observed from week 4 to
end of treatment, suggesting a sustained LDL-C-lowering ef-
fect with alirocumab. Despite very high baseline LDL-C
levels, 41.0 % of patients receiving alirocumab achieved their
pre-defined LDL-C goals of < 70 mg/dl or < 100 mg/dl, de-
pending on cardiovascular risk. Regardless of prior cardiovas-
cular events, 32.4 and 57.0 % of patients reached the LDL-C
levels of < 70 and < 100 mg/dl, respectively, which have been
defined as treatment targets in FH guidelines [1, 2, 36–38].
Incremental lowering of LDL-C levels to below previously
defined targets with the addition of ezetimibe to statin therapy
has been demonstrated to improve cardiovascular outcomes
[5]. Several large clinical outcomes studies with PCSK9mono-
clonal antibodies including alirocumab [39] are ongoing.
Compared with ezetimibe, alirocumab provides a greater incre-
mental reduction in LDL-C levels when added to statin therapy
[20, 21]; the results of the ongoing clinical ODYSSEY
OUTCOMES study (NCT01663402) will help to establish
whether this also translates into a beneficial reduction in car-
diovascular events [39]. Furthermore, consistent with previous
ODYSSEYphase 3 studies [19–21, 24, 25], alirocumab signif-
icantly reduced Lp(a) levels; an additional benefit not observed
with ezetimibe treatment when added to statin therapy [5].
The incidence of TEAEs was broadly similar in the
alirocumab-treated and placebo groups, with a comparable
incidence of AEs leading to treatment discontinuation be-
tween both groups. The overall rate of AEs of special interest
was low, including TEAEs related to allergic events, as well as
hepatitis, ophthalmologic, neurologic, and neurocognitive dis-
orders. There was an imbalance in treatment-emergent cardio-
vascular events confirmed by adjudication, which were report-
ed by six alirocumab-treated patients (8.3 %) compared with
no placebo patients. It should be noted, however, that the
current study is not adequately powered to look at differences
in adjudicated cardiovascular events and the number of pa-
tients randomized in HIGH FH was small (n = 107). In a
previous study with 2341 randomized patients treated for
78 weeks, alirocumab indicated a reduction of cardiovascular
events in a post-hoc analysis [25]; however, additional data
are required to confirm this observation. Safety across all
alirocumab phase 2 and 3 trials has been analyzed in a large
pooled database, and cardiovascular outcomes are being for-
mally assessed in the ongoing 18,000-patient ODYSSEY
OUTCOMES study [39]. No deaths occurred during the
study. No cases of chorioretinopathy have been previously
reported in the other trials in the ODYSSEY program [20,
21, 23–25]. The safety data are consistent with previous phase
3 ODYSSEY studies demonstrating no excess of AEs in
alirocumab-treated patients [20, 21, 23–25].
In conclusion, this study showed that self-administered
alirocumab 150 mg Q2W in patients with heFH and LDL-
C ≥ 160 mg/dl at baseline produced a significant decrease in
LDL-C from baseline to week 24 versus placebo (LDL-C
decrease of 90.8 mg/dl) on top of statin and other LLT with
a compliance of 98 % to study medication at week 78.
Alirocumab was generally well tolerated, with TEAEs
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comparable with placebo. These findings further support the
use of alirocumab as a therapeutic option in patients with
heFH, potentially allowing for reduction in LDL-C to levels
that were previously unobtainable using existing standard of
care therapies. Ongoing clinical outcomes studies of PCSK9
monoclonal antibodies will help to establish potential clinical
benefits of these therapies.
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